RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000075.xml
PDF herunterladen
Semin Respir Crit Care Med 2013; 34(04): 487-498
DOI: 10.1055/s-0033-1351119
DOI: 10.1055/s-0033-1351119
Treatment of Acute Lung Injury: Current and Emerging Pharmacological Therapies
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
11. August 2013 (online)
Abstract
As a syndrome of injurious pulmonary inflammation resulting in deranged respiratory physiology, acute lung injury affords numerous potential therapeutic targets. Two main pharmacological treatment strategies have arisen—the attempted inhibition of excessive inflammation or the manipulation of the resulting physiological derangement causing respiratory failure. Additionally, such interventions may allow the delivery of less injurious mechanical ventilation. An emerging approach is the use of cell-based therapy, which, rather than inhibiting the inflammatory process, seeks to convert it from an injurious process to a reparative one. This review outlines previous, current, and emerging pharmacological therapies for acute lung injury.
-
References
- 1 Gattinoni L, Pelosi P, Suter PM, Pedoto A, Vercesi P, Lissoni A. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes?. Am J Respir Crit Care Med 1998; 158 (1) 3-11
- 2 Gadek JE, DeMichele SJ, Karlstad MD , et al; Enteral Nutrition in ARDS Study Group. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit Care Med 1999; 27 (8) 1409-1420
- 3 Pacht ER, DeMichele SJ, Nelson JL, Hart J, Wennberg AK, Gadek JE. Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 2003; 31 (2) 491-500
- 4 Pontes-Arruda A, Aragão AMA, Albuquerque JD. Effects of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock. Crit Care Med 2006; 34 (9) 2325-2333
- 5 Singer P, Theilla M, Fisher H, Gibstein L, Grozovski E, Cohen J. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006; 34 (4) 1033-1038
- 6 Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008; 34 (11) 1980-1990
- 7 Rice TW, Wheeler AP, Thompson BT, deBoisblanc BP, Steingrub J, Rock P. NIH NHLBI Acute Respiratory Distress Syndrome Network of Investigators. Enteral omega-3 fatty acid, γ-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306 (14) 1574-1581
- 8 Stapleton RD, Martin TR, Weiss NS , et al. A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury. Crit Care Med 2011; 39 (7) 1655-1662
- 9 Cook DJ, Heyland DK. Pharmaconutrition in acute lung injury. JAMA 2011; 306 (14) 1599-1600
- 10 Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991; 100 (5) 1397-1403
- 11 Bernard GR, Wheeler AP, Arons MM , et al; The Antioxidant in ARDS Study Group. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997; 112 (1) 164-172
- 12 Ortolani O, Conti A, De Gaudio AR, Masoni M, Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000; 13 (1) 14-18
- 13 Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20 (7) 819-923
- 14 Suter PM, Domenighetti G, Schaller MD, Laverrière MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105 (1) 190-194
- 15 Domenighetti G, Suter PM, Schaller M-D, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997; 12 (4) 177-182
- 16 Montravers P, Fagon JY, Gilbert C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest 1993; 103 (4) 1017-1022
- 17 The Acute Respiratory Disease Syndrome Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30 (1) 1-6
- 18 Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 2003; 31 (4, Suppl): S189-S194
- 19 Tamakuma S, Shiba T, Hirasawa H , et al. A phase III clinical study of neutrophil elastase inhibitor ONO-5046 Na in SIRS patients. J Clin Ther Med (Japan) 1998; 14: 289-318
- 20 Zeiher BG, Artigas A, Vincent JL , et al; STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004; 32 (8) 1695-1702
- 21 Iwata K, Doi A, Ohji G , et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med 2010; 49 (22) 2423-2432
- 22 Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28 (5) 648-654
- 23 The ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000; 283 (15) 1995-2002
- 24 Rosenberg AL, Dechert RE, Park PK, Bartlett RH. The National Heart L, Blood Institute ARDSCTN. Review of A Large Clinical Series: Association of Cumulative Fluid Balance on Outcome in Acute Lung Injury: A Retrospective Review of the ARDSnet Tidal Volume Study Cohort. J Intensive Care Med 2009; 24 (1) 35-46
- 25 Sakr Y, Vincent J-L, Reinhart K , et al; Sepsis Occurence in Acutely Ill Patients Investigators. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest 2005; 128 (5) 3098-3108
- 26 Davey-Quinn A, Gedney JA, Whiteley SM, Bellamy MC. Extravascular lung water and acute respiratory distress syndrome—oxygenation and outcome. Anaesth Intensive Care 1999; 27 (4) 357-362
- 27 Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990; 97 (5) 1176-1180
- 28 Wiedemann HP, Wheeler AP, Bernard GR , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354 (24) 2564-2575
- 29 Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-agonists and the acute respiratory distress syndrome. Crit Care 2004; 8 (1) 25-32
- 30 Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994; 106 (5) 1517-1523
- 31 Pesenti A, Pelosi P, Rossi N, Aprigliano M, Brazzi L, Fumagalli R. Respiratory mechanics and bronchodilator responsiveness in patients with the adult respiratory distress syndrome. Crit Care Med 1993; 21 (1) 78-83
- 32 Moriña P, Herrera M, Venegas J, Mora D, Rodríguez M, Pino E. Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med 1997; 23 (1) 58-64
- 33 Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173 (3) 281-287
- 34 Basran GS, Hardy JG, Woo SP, Ramasubramanian R, Byrne AJ. Beta-2-adrenoceptor agonists as inhibitors of lung vascular permeability to radiolabelled transferrin in the adult respiratory distress syndrome in man. Eur J Nucl Med 1986; 12 (8) 381-384
- 35 Licker M, Tschopp J-M, Robert J, Frey J-G, Diaper J, Ellenberger C. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 2008; 133 (4) 845-852
- 36 Manocha S, Gordon AC, Salehifar E, Groshaus H, Walley KR, Russell JA. Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care 2006; 10 (1) R12
- 37 Matthay MA, Brower RG, Carson S , et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184 (5) 561-568
- 38 Gao Smith F, Perkins GD, Gates S , et al; BALTI-2 study investigators. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379 (9812) 229-235
- 39 Bassford CR, Thickett DR, Perkins GD. The rise and fall of β-agonists in the treatment of ARDS. Crit Care 2012; 16 (2) 208
- 40 Price LC, McAuley DF, Marino PS, Finney SJ, Griffiths MJ, Wort SJ. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 302 (9) L803-L815
- 41 Siobal MS, Hess DR. Are inhaled vasodilators useful in acute lung injury and acute respiratory distress syndrome?. Respir Care 2010; 55 (2) 144-157 , discussion 157–161
- 42 Lowson SM. Alternatives to nitric oxide. Br Med Bull 2004; 70 (1) 119-131
- 43 Cuthbertson BH, Galley HF, Webster NR. Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury. Crit Care Med 2000; 28 (6) 1736-1741
- 44 Day RW, Allen EM, Witte MKA. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest 1997; 112 (5) 1324-1331
- 45 Dellinger RP, Zimmerman JL, Taylor RW , et al; Inhaled Nitric Oxide in ARDS Study Group. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998; 26 (1) 15-23
- 46 Dobyns EL, Cornfield DN, Anas NG , et al. Multicenter randomized controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxemic respiratory failure. J Pediatr 1999; 134 (4) 406-412
- 47 Gerlach H, Keh D, Semmerow A , et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003; 167 (7) 1008-1015
- 48 Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. The European Study Group of Inhaled Nitric Oxide. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med 1999; 25 (9) 911-919
- 49 Mehta S, Simms H, Levy M , et al. Inhaled nitric oxide improves oxygenation acutely but not chronically in acute respiratory distress syndrome: a randomized, controlled trial. Journal of Applied Research 2001; 1 (2) 73-84
- 50 Michael JR, Barton RG, Saffle JR , et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998; 157 (5 Pt 1) 1372-1380
- 51 Park KJ, Lee YJ, Oh YJ, Lee KS, Sheen SS, Hwang SC. Combined effects of inhaled nitric oxide and a recruitment maneuver in patients with acute respiratory distress syndrome. Yonsei Med J 2003; 44 (2) 219-226
- 52 Taylor RW, Zimmerman JL, Dellinger RP , et al; Inhaled Nitric Oxide in ARDS Study Group. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291 (13) 1603-1609
- 53 Angus DC, Clermont G, Linde-Zwirble WT , et al; NO-06 Investigators. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide. Crit Care Med 2006; 34 (12) 2883-2890
- 54 Troncy E, Collet J-P, Shapiro S , et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157 (5 Pt 1) 1483-1488
- 55 Creagh-Brown BC, Griffiths MJ, Evans TW. Bench-to-bedside review: inhaled nitric oxide therapy in adults. Crit Care 2009; 13 (3) 221
- 56 Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a meta-analysis. Anesth Analg 2003; 97 (4) 989-998
- 57 Adhikari NKJ, Burns KEA, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007; 334 (7597) 779
- 58 Afshari A, Brok J, Møller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg 2011; 112 (6) 1411-1421
- 59 Dahlem P, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med 2004; 32 (4) 1055-1060
- 60 Zwissler B, Kemming G, Habler O , et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154 (6 Pt 1) 1671-1677
- 61 Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153 (3) 991-996
- 62 Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS—a pilot study. Anaesth Intensive Care 1996; 24 (5) 564-568
- 63 Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg 1986; 203 (4) 371-378
- 64 Bone RC, Slotman G, Maunder R , et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989; 96 (1) 114-119
- 65 Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology 1990; 72 (2) 276-281
- 66 Abraham E, Baughman R, Fletcher E , et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 1999; 27 (8) 1478-1485
- 67 Vincent JL, Brase R, Santman F , et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001; 27 (10) 1578-1583
- 68 Reyes A, Roca J, Rodriguez-Roisin R, Torres A, Ussetti P, Wagner PD. Effect of almitrine on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137 (5) 1062-1067
- 69 Gallart L, Lu QIN, Puybasset L, Umamaheswara Rao GS, Coriat P, Rouby JJ. The NO Almitrine Study Group. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158 (6) 1770-1777
- 70 Wysocki M, Delclaux C, Roupie E , et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med 1994; 20 (4) 254-259
- 71 Liu KD, Levitt J, Zhuo H , et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178 (6) 618-623
- 72 Ranieri VM, Thompson BT, Barie PS , et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22) 2055-2064
- 73 Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009; 30 (2) 249-256
- 74 Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008; 12 (3) R64
- 75 Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD. Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010; 14 (5) 445
- 76 Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010; 14 (5) R180
- 77 Laterre PF, Wittebole X, Dhainaut JF. Anticoagulant therapy in acute lung injury. Crit Care Med 2003; 31 (4, Suppl): S329-S336
- 78 MacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007; 27 (6) 860-873
- 79 Nieuwenhuizen L, de Groot PG, Grutters JC, Biesma DH. A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia. Eur J Haematol 2009; 82 (6) 413-425
- 80 Tuinman PR, Dixon B, Levi M, Juffermans NP, Schultz MJ. Nebulized anticoagulants for acute lung injury: a systematic review of preclinical and clinical investigations. Crit Care 2012; 16 (2) R70
- 81 Raoof S, Goulet K, Esan A, Hess DR, Sessler CN. Severe hypoxemic respiratory failure, II: Nonventilatory strategies. Chest 2010; 137 (6) 1437-1448
- 82 Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses, pharmacology, and clinical considerations of neuromuscular blocking agents for critically ill adults. Ann Pharmacother 2011; 45 (9) 1116-1126
- 83 Forel J-M, Roch A, Marin V , et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006; 34 (11) 2749-2757
- 84 Deem S, Lee CM, Curtis JR. Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med 2003; 168 (7) 735-739
- 85 Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care 2008; 12 (6) 238
- 86 Arroliga A, Frutos-Vivar F, Hall J , et al; International Mechanical Ventilation Study Group. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128 (2) 496-506
- 87 Gainnier M, Roch A, Forel J-M , et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004; 32 (1) 113-119
- 88 Papazian L, Forel J-M, Gacouin A , et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363 (12) 1107-1116
- 89 Rudis MI, Sikora CA, Angus E , et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997; 25 (4) 575-583
- 90 Frerking I, Günther A, Seeger W, Pison U. Pulmonary surfactant: functions, abnormalities and therapeutic options. Intensive Care Med 2001; 27 (11) 1699-1717
- 91 Kesecioglu J, Schultz M, Lundberg D, Lauven P, Assael BM. Treatment of acute lung injury (ALI/ARDS) with surfactant [abstract]. Am J Respir Crit Care Med 2001; 163: A819
- 92 Kesecioglu J, Schultz M, Maas J, De Wilde R, Steenken E, Lachmann B. Treatment of acute lung injury and ARDS with surfactant is safe [abstract]. Am J Respir Crit Care Med 2004; 169: A349
- 93 Kesecioglu J, Beale R, Stewart TE , et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009; 180 (10) 989-994
- 94 Spragg RG, Lewis JF, Wurst W , et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167 (11) 1562-1566
- 95 Anzueto A, Baughman RP, Guntupalli KK , et al; Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334 (22) 1417-1421
- 96 Spragg RG, Lewis JF, Walmrath H-D , et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351 (9) 884-892
- 97 Spragg RG, Taut FJH, Lewis JF , et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011; 183 (8) 1055-1061
- 98 Davidson WJ, Dorscheid D, Spragg RG, Schulzer M, Mak E, Ayas NT. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10 (2) R41
- 99 Stevens TP, Sinkin RA. Surfactant replacement therapy. Chest 2007; 131 (5) 1577-1582
- 100 Craig T, O'Kane CM, McAuley DF. Potential mechanisms by which statins modulate pathogenic mechanisms important in the development of acute lung injury. In: Vincent JL, ed. 27th Yearbook of Intensive Care and Emergency Medicine. Berlin, Germany: Springer-Verlag; 2007: 287-300
- 101 Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respir Med 2010; 104 (8) 1081-1091
- 102 Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med 2009; 35 (6) 1039-1046
- 103 Irish Critical Care Trials Group. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care 2008; 12 (1) R30
- 104 Bajwa EK, Malhotra CK, Thompson BT, Christiani DC, Gong MN. Statin therapy as prevention against development of acute respiratory distress syndrome: an observational study. Crit Care Med 2012; 40 (5) 1470-1477
- 105 O'Neal Jr HRJ, Koyama T, Koehler EAS , et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39 (6) 1343-1350
- 106 Shyamsundar M, McKeown ST, O'Kane CM , et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009; 179 (12) 1107-1114
- 107 Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit Care Med 2009; 37 (8) 2455-2464
- 108 Donnelly M, Condron C, Murray P, Bouchier-Hayes D. Modulation of the glycemic response using insulin attenuates the pulmonary response in an animal trauma model. J Trauma 2007; 63 (2) 351-357
- 109 Chen HI, Yeh DY, Liou H-L, Kao S-J. Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med 2006; 34 (3) 758-764
- 110 van den Berghe G, Wouters P, Weekers F , et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345 (19) 1359-1367
- 111 Kuba K, Imai Y, Rao S , et al. A crucial role of angiotensin converting enzyme 2
(ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11 (8) 875-879
MissingFormLabel
- 112 Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008; 93 (5) 543-548
- 113 Marshall RP, Webb S, Bellingan GJ , et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166 (5) 646-650
- 114 Jerng J-S, Yu C-J, Wang H-C, Chen K-Y, Cheng S-L, Yang P-C. Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome. Crit Care Med 2006; 34 (4) 1001-1006
- 115 Orfanos SE, Armaganidis A, Glynos C , et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 2000; 102 (16) 2011-2018
- 116 Imai Y, Kuba K, Rao S , et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436 (7047) 112-116
- 117 Hofstra JJ, Levi M, Schultz MJ. HETRASE study—did heparin treatment benefit patients with ALI/ARDS?. Crit Care Med 2009; 37 (8) 2490
- 118 Noto MJ, Wheeler AP. Macrolides for acute lung injury. Chest 2012; 141 (5) 1131-1132
- 119 Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141 (5) 1153-1159
- 120 Matthay MA. Advances and challenges in translating stem cell therapies for clinical diseases. Transl Res 2010; 156 (3) 107-111
- 121 van Poll D, Parekkadan B, Borel Rinkes IH, Tilles AW, Yarmush ML. Mesenchymal stem cell therapy for protection and repair of injured vital organs. Cell Mol Bioeng 2008; 1 (1) 42-50
- 122 Gupta N, Krasnodembskaya A, Kapetanaki M , et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012; 67 (6) 533-539
- 123 Curley GF, Hayes M, Ansari B , et al. Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. Thorax 2012; 67 (6) 496-501
- 124 Mac Sweeney R, McAuley DF. Mesenchymal stem cell therapy in acute lung injury: is it time for a clinical trial?. Thorax 2012; 67 (6) 475-476
- 125 Paine III RI, Standiford TJ, Dechert RE , et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40 (1) 90-97
- 126 Qian L, Huang Y, Spencer CI , et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012; 485 (7400) 593-598